Top-Rated StocksTop-RatedNASDAQ:LEGN Legend Biotech (LEGN) Stock Forecast, Price & News $67.17 -0.14 (-0.21%) (As of 09/29/2023 ET) Add Compare Share Share Today's Range$66.72▼$68.2350-Day Range$63.16▼$76.5052-Week Range$37.30▼$77.32Volume525,950 shsAverage Volume442,805 shsMarket Capitalization$11.09 billionP/E RatioN/ADividend YieldN/APrice Target$80.90 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Legend Biotech MarketRank™ ForecastAnalyst RatingModerate Buy2.87 Rating ScoreUpside/Downside20.4% Upside$80.90 Price TargetShort InterestBearish4.37% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.93Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.60) to ($1.61) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.57 out of 5 starsMedical Sector893rd out of 972 stocksPharmaceutical Preparations Industry412th out of 444 stocks 2.4 Analyst's Opinion Consensus RatingLegend Biotech has received a consensus rating of Moderate Buy. The company's average rating score is 2.87, and is based on 13 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $80.90, Legend Biotech has a forecasted upside of 20.4% from its current price of $67.17.Amount of Analyst CoverageLegend Biotech has only been the subject of 4 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.37% of the outstanding shares of Legend Biotech have been sold short.Short Interest Ratio / Days to CoverLegend Biotech has a short interest ratio ("days to cover") of 13.4, which indicates bearish sentiment.Change versus previous monthShort interest in Legend Biotech has recently decreased by 2.83%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldLegend Biotech does not currently pay a dividend.Dividend GrowthLegend Biotech does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LEGN. Previous Next 2.7 News and Social Media Coverage News SentimentLegend Biotech has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Legend Biotech this week, compared to 3 articles on an average week.Search Interest4 people have searched for LEGN on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Legend Biotech insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.02% of the stock of Legend Biotech is held by insiders.Percentage Held by Institutions49.61% of the stock of Legend Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Legend Biotech are expected to grow in the coming year, from ($2.60) to ($1.61) per share.Price to Book Value per Share RatioLegend Biotech has a P/B Ratio of 14.80. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Legend Biotech (NASDAQ:LEGN) StockLegend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia , gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.Read More LEGN Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LEGN Stock News HeadlinesSeptember 25, 2023 | americanbankingnews.comLegend Biotech Co. (NASDAQ:LEGN) Receives $80.90 Average Target Price from AnalystsAugust 21, 2023 | seekingalpha.comLegend Biotech: Working On Supply IssuesOctober 1, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.August 16, 2023 | markets.businessinsider.comLegend Biotech (LEGN) Receives a Buy from BarclaysAugust 16, 2023 | finance.yahoo.comQ2 2023 Legend Biotech Corp Earnings CallAugust 15, 2023 | finance.yahoo.comLegend Biotech Reports Second Quarter 2023 Results and Recent HighlightsAugust 14, 2023 | finance.yahoo.comWhy Earnings Season Could Be Great for Legend Biotech (LEGN)August 3, 2023 | finance.yahoo.comLegend Biotech to Host Investor Conference Call on Second-Quarter ResultsOctober 1, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.July 21, 2023 | msn.comMorgan Stanley Maintains Legend Biotech Corp - ADR (LEGN) Overweight RecommendationJuly 7, 2023 | seekingalpha.comDespite High Share Price, Legend Bio Looks Like A WinnerJune 29, 2023 | finance.yahoo.comThis Top-Performing Small-Cap Manager Is Betting Big on ChinaJune 12, 2023 | markets.businessinsider.comBTIG Keeps Their Buy Rating on Legend Biotech (LEGN)June 7, 2023 | markets.businessinsider.comPiper Sandler Reaffirms Their Buy Rating on Legend Biotech (LEGN)June 7, 2023 | finance.yahoo.comLegend (LEGN) Up 4% on sNDA Submission for Carvykti Expanded UseJune 7, 2023 | msn.comHC Wainwright & Co. Maintains Legend Biotech Corp - ADR (LEGN) Buy RecommendationJune 6, 2023 | finance.yahoo.comLegend Biotech Announces Submission of Supplemental Application to the U.S. FDA for Expanded Use of CARVYKTI® (ciltacabtagene autoleucel)June 5, 2023 | finance.yahoo.comCiltacabtagene Autoleucel (cilta-cel) Reduced Risk of Disease Progression or Death by 74% vs Standard Regimens for Adult Patients with Relapsed and Refractory Multiple Myeloma in CARTITUDE-4 StudyMay 25, 2023 | markets.businessinsider.comExpert Ratings for Legend BiotechMay 25, 2023 | msn.comWilliam Blair Initiates Coverage of Legend Biotech Corp - ADR (LEGN) with Market Perform RecommendationMay 25, 2023 | finance.yahoo.comLegend Biotech Announces Submission to the European Medicines Agency for Expanded Use of CARVYKTI® (ciltacabtagene autoleucel)May 23, 2023 | finance.yahoo.comLegend Biotech's Story Is Still Playing OutMay 22, 2023 | msn.comHC Wainwright & Co. Reiterates Legend Biotech Corp - ADR (LEGN) Buy RecommendationMay 22, 2023 | msn.comDaiwa Capital Initiates Coverage of Legend Biotech Corp - ADR (LEGN) with Buy RecommendationMay 19, 2023 | msn.comBarclays Maintains Legend Biotech Corp - ADR (LEGN) Overweight RecommendationMay 19, 2023 | msn.comRBC Capital Maintains Legend Biotech Corp - ADR (LEGN) Outperform RecommendationMay 19, 2023 | markets.businessinsider.comPiper Sandler Sticks to Their Buy Rating for Legend Biotech (LEGN)See More Headlines Receive LEGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Legend Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address LEGN Company Calendar Last Earnings8/15/2023Today9/30/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:LEGN CUSIPN/A CIK1801198 Webwww.legendbiotech.com Phone732-317-5050FaxN/AEmployees1,390Year FoundedN/APrice Target and Rating Average Stock Price Forecast$80.90 High Stock Price Forecast$92.00 Low Stock Price Forecast$64.00 Forecasted Upside/Downside+20.4%Consensus RatingModerate Buy Rating Score (0-4)2.87 Research Coverage15 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.19 Current Ratio8.01 Quick Ratio7.93 Sales & Book Value Annual Sales$164.66 million Price / Sales67.34 Cash FlowN/A Price / Cash FlowN/A Book Value$4.54 per share Price / Book14.80Miscellaneous Outstanding Shares165,067,000Free Float165,034,000Market Cap$11.09 billion OptionableNot Optionable Beta0.02 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesDr. Ying Huang Ph.D. (Age 50)CEO & Director Ms. Lori A. Macomber CPA (Age 52)Chief Financial Officer Dr. Guowei Fang Ph.D.Chief Scientific Officer & Head of Bus. Devel.Joanne ChoiSr. Mang. of Investor RelationsDeborah WongExec. Director of Strategic Marketing & Corp. CommunicationsMs. Elaine QianVP & Global Head of HRMs. Liz GosenSr. VP of Technical OperationsDr. Yuhong Qiu Ph.D.Sr. VP of Global Regulatory AffairsMr. Steven J. GavelSr. VP of Commercial Devel., US & EuropeMr. Alan KickSr. VP of Global QualityMore ExecutivesKey CompetitorsSarepta TherapeuticsNASDAQ:SRPTVerona PharmaNASDAQ:VRNAUnited TherapeuticsNASDAQ:UTHRDr. Reddy's LaboratoriesNYSE:RDYViatrisNASDAQ:VTRSView All CompetitorsInstitutional OwnershipCalifornia State Teachers Retirement SystemSold 3,709 shares on 8/21/2023Ownership: 0.009%Legato Capital Management LLCSold 2,647 shares on 8/18/2023Ownership: 0.005%Coppell Advisory Solutions LLCBought 586 shares on 8/17/2023Ownership: 0.000%National Pension ServiceBought 5,470 shares on 8/16/2023Ownership: 0.013%Atlas Capital Advisors LLCBought 821 shares on 8/15/2023Ownership: 0.000%View All Institutional Transactions LEGN Stock - Frequently Asked Questions Should I buy or sell Legend Biotech stock right now? 15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Legend Biotech in the last twelve months. There are currently 2 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" LEGN shares. View LEGN analyst ratings or view top-rated stocks. What is Legend Biotech's stock price forecast for 2023? 15 brokers have issued 1 year target prices for Legend Biotech's shares. Their LEGN share price forecasts range from $64.00 to $92.00. On average, they anticipate the company's share price to reach $80.90 in the next twelve months. This suggests a possible upside of 20.4% from the stock's current price. View analysts price targets for LEGN or view top-rated stocks among Wall Street analysts. How have LEGN shares performed in 2023? Legend Biotech's stock was trading at $49.92 at the beginning of 2023. Since then, LEGN shares have increased by 34.6% and is now trading at $67.17. View the best growth stocks for 2023 here. How were Legend Biotech's earnings last quarter? Legend Biotech Co. (NASDAQ:LEGN) posted its earnings results on Tuesday, August, 15th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.36) by $0.21. The business earned $73.30 million during the quarter, compared to analysts' expectations of $56.64 million. The business's quarterly revenue was up 510.8% compared to the same quarter last year. What ETFs hold Legend Biotech's stock? ETFs with the largest weight of Legend Biotech (NASDAQ:LEGN) stock in their portfolio include Global X MSCI China Health Care ETF (CHIH), Loncar China Biopharma ETF (CHNA), Harbor Health Care ETF (MEDI), Virtus LifeSci Biotech Products ETF (BBP), KraneShares MSCI All China Health Care Index ETF (KURE), Fidelity Disruptive Medicine ETF (FMED), BlackRock Future Health ETF (BMED) and Range Cancer Therapeutics ETF (CNCR). What other stocks do shareholders of Legend Biotech own? Based on aggregate information from My MarketBeat watchlists, some companies that other Legend Biotech investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), CrowdStrike (CRWD), Lam Research (LRCX), ServiceNow (NOW), Peloton Interactive (PTON), QUALCOMM (QCOM), Applied Materials (AMAT), DocuSign (DOCU) and Etsy (ETSY). When did Legend Biotech IPO? (LEGN) raised $350 million in an initial public offering on Friday, June 5th 2020. The company issued 18,400,000 shares at $18.00-$20.00 per share. Morgan Stanley, J.P. Morgan Securities and Jefferies served as the underwriters for the IPO. What is Legend Biotech's stock symbol? Legend Biotech trades on the NASDAQ under the ticker symbol "LEGN." How do I buy shares of Legend Biotech? Shares of LEGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Legend Biotech's stock price today? One share of LEGN stock can currently be purchased for approximately $67.17. How much money does Legend Biotech make? Legend Biotech (NASDAQ:LEGN) has a market capitalization of $11.09 billion and generates $164.66 million in revenue each year. How many employees does Legend Biotech have? The company employs 1,390 workers across the globe. How can I contact Legend Biotech? Legend Biotech's mailing address is 2101 COTTONTAIL LANE, SOMERSET NJ, 08873. The official website for the company is www.legendbiotech.com. The company can be reached via phone at 732-317-5050 or via email at investor@legendbiotech.com. This page (NASDAQ:LEGN) was last updated on 10/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Legend Biotech Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.